Vimarsana
Biggest News Aggregation in the World

Page 6 - Mayo Collaborative Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mayo Collaborative Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mayo Collaborative Services Today - Breaking & Trending Today

Can Judge Michel (and John Duffy) Convince the Supreme Court to Revisit Subject Matter Eligibility? | McDonnell Boehnen Hulbert & Berghoff LLP - Vimarsana News

Can Judge Michel (and John Duffy) Convince the Supreme Court to Revisit Subject Matter Eligibility? | McDonnell Boehnen Hulbert & Berghoff LLP

Einstein's aphorism that doing the same thing over and over again and expecting a different outcome is a hallmark of madness (or at least an inability to learn from the past) inevitably...

Stanford Asks Supreme Court to Revisit Subject Matter Eligibility on Diagnostic Claims | McDonnell Boehnen Hulbert & Berghoff LLP - Vimarsana News

Stanford Asks Supreme Court to Revisit Subject Matter Eligibility on Diagnostic Claims | McDonnell Boehnen Hulbert & Berghoff LLP

"Hope springs eternal [in the human breast]" (Alexander Pope) and "Insanity is doing the same thing over and over and expecting different results" (the latter attributed variably to...

Why Is the U.S. Solicitor General Trying To Change The Law To Benefit Patent Trolls? - Vimarsana News

Why Is the U.S. Solicitor General Trying To Change The Law To Benefit Patent Trolls?

For more than two decades now, developers and users of software have been plagued by a flood of bad patents. Software patents that describe everyday practices like watching an ad online, publishing nutrition information, meeting people nearby, or teaching a language class continue to be issued, and...

Source: eff.org
Merck to Acquire Prometheus Biosciences for $10.8B - Vimarsana News

Merck to Acquire Prometheus Biosciences for $10.8B

Merck & Co. has agreed to acquire Prometheus Biosciences for about $10.8 billion, the companies said Sunday.

Patent Eligibility of Medical Diagnostic Methods - Vimarsana News

Patent Eligibility of Medical Diagnostic Methods

In CareDx, Inc. v. Natera, Inc., Court of Appeals for the Federal Circuit held CareDx’s patent claims to methods of detecting organ transplant rejection were invalid as patent ineligible under 35 U.S.C. section 101. Claims to medical diagnostics face unique challenges.